| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Editing | 30 | 2024 | 299 | 8.430 |
Why?
|
| CRISPR-Cas Systems | 31 | 2024 | 335 | 8.190 |
Why?
|
| Liver Neoplasms | 15 | 2021 | 277 | 3.680 |
Why?
|
| Carcinoma, Hepatocellular | 11 | 2021 | 167 | 2.790 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2019 | 289 | 1.670 |
Why?
|
| Mice | 51 | 2023 | 10316 | 1.660 |
Why?
|
| Hepatocytes | 9 | 2024 | 196 | 1.630 |
Why?
|
| Hepatoblastoma | 2 | 2022 | 8 | 1.510 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2022 | 411 | 1.440 |
Why?
|
| Animals | 56 | 2024 | 19705 | 1.370 |
Why?
|
| Exons | 4 | 2023 | 195 | 1.320 |
Why?
|
| Liver Neoplasms, Experimental | 6 | 2016 | 32 | 1.310 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 6 | 2018 | 91 | 1.310 |
Why?
|
| Genes, Tumor Suppressor | 7 | 2018 | 70 | 1.280 |
Why?
|
| Tyrosinemias | 6 | 2022 | 19 | 1.270 |
Why?
|
| Adenine | 2 | 2020 | 50 | 1.270 |
Why?
|
| DNA | 7 | 2023 | 806 | 1.240 |
Why?
|
| Liver | 10 | 2022 | 798 | 1.220 |
Why?
|
| Lung Neoplasms | 6 | 2017 | 604 | 1.130 |
Why?
|
| Carcinogenesis | 4 | 2021 | 119 | 1.080 |
Why?
|
| Dependovirus | 8 | 2024 | 653 | 1.080 |
Why?
|
| Genome, Human | 4 | 2018 | 225 | 1.070 |
Why?
|
| Cell Line, Tumor | 14 | 2022 | 1380 | 1.060 |
Why?
|
| Genomics | 7 | 2016 | 322 | 1.040 |
Why?
|
| Genetic Vectors | 9 | 2024 | 809 | 1.010 |
Why?
|
| Proprotein Convertase 9 | 4 | 2022 | 12 | 0.990 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 3 | 2024 | 62 | 0.950 |
Why?
|
| Genetic Therapy | 6 | 2024 | 735 | 0.940 |
Why?
|
| Genome | 8 | 2023 | 257 | 0.920 |
Why?
|
| Lung | 4 | 2024 | 926 | 0.910 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2022 | 482 | 0.880 |
Why?
|
| Macaca mulatta | 1 | 2024 | 229 | 0.850 |
Why?
|
| Mutation | 11 | 2024 | 2462 | 0.750 |
Why?
|
| Adenylosuccinate Lyase | 1 | 2021 | 2 | 0.740 |
Why?
|
| Purines | 1 | 2021 | 38 | 0.730 |
Why?
|
| Genetic Engineering | 3 | 2021 | 111 | 0.710 |
Why?
|
| Alternative Splicing | 2 | 2018 | 122 | 0.700 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2017 | 55 | 0.680 |
Why?
|
| Disease Models, Animal | 11 | 2023 | 2060 | 0.670 |
Why?
|
| HEK293 Cells | 8 | 2021 | 588 | 0.660 |
Why?
|
| Humans | 50 | 2024 | 59737 | 0.650 |
Why?
|
| Transcription Factors | 6 | 2022 | 1473 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2017 | 98 | 0.640 |
Why?
|
| Gene Knock-In Techniques | 1 | 2019 | 34 | 0.630 |
Why?
|
| Genes, ras | 1 | 2019 | 27 | 0.630 |
Why?
|
| Cholangiocarcinoma | 1 | 2019 | 28 | 0.630 |
Why?
|
| Bile Duct Neoplasms | 1 | 2019 | 43 | 0.620 |
Why?
|
| Adenocarcinoma | 4 | 2017 | 327 | 0.600 |
Why?
|
| Neoplasms | 7 | 2021 | 1238 | 0.580 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 150 | 0.580 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2018 | 87 | 0.550 |
Why?
|
| Hydrogen Sulfide | 1 | 2017 | 5 | 0.550 |
Why?
|
| Oncogenes | 4 | 2014 | 66 | 0.540 |
Why?
|
| fas Receptor | 1 | 2017 | 55 | 0.530 |
Why?
|
| Alleles | 5 | 2024 | 412 | 0.530 |
Why?
|
| Liver Diseases | 1 | 2018 | 138 | 0.530 |
Why?
|
| Antibodies | 1 | 2017 | 179 | 0.510 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2016 | 208 | 0.490 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 38 | 0.480 |
Why?
|
| Cellular Senescence | 3 | 2019 | 104 | 0.480 |
Why?
|
| Nuclear Proteins | 2 | 2019 | 750 | 0.470 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1472 | 0.450 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2015 | 71 | 0.450 |
Why?
|
| Mutagenesis | 1 | 2014 | 128 | 0.440 |
Why?
|
| MicroRNAs | 3 | 2019 | 627 | 0.440 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 860 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2012 | 22 | 0.400 |
Why?
|
| Monosomy | 1 | 2012 | 2 | 0.400 |
Why?
|
| Signal Transduction | 6 | 2017 | 2905 | 0.390 |
Why?
|
| NF-kappa B | 2 | 2011 | 459 | 0.380 |
Why?
|
| Genes, Reporter | 4 | 2022 | 243 | 0.360 |
Why?
|
| Gene Deletion | 1 | 2012 | 293 | 0.350 |
Why?
|
| ras Proteins | 3 | 2016 | 77 | 0.350 |
Why?
|
| Endonucleases | 3 | 2023 | 80 | 0.350 |
Why?
|
| RNA Interference | 7 | 2015 | 591 | 0.340 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 632 | 0.330 |
Why?
|
| Wnt Proteins | 3 | 2017 | 94 | 0.330 |
Why?
|
| Plasmids | 4 | 2020 | 281 | 0.330 |
Why?
|
| Transfection | 3 | 2021 | 679 | 0.320 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 395 | 0.320 |
Why?
|
| Gene Knockout Techniques | 2 | 2021 | 88 | 0.310 |
Why?
|
| Transcription, Genetic | 4 | 2018 | 844 | 0.310 |
Why?
|
| Genes, p53 | 4 | 2019 | 52 | 0.300 |
Why?
|
| beta Catenin | 4 | 2017 | 88 | 0.290 |
Why?
|
| Promoter Regions, Genetic | 4 | 2019 | 653 | 0.280 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 727 | 0.280 |
Why?
|
| Chromatin | 2 | 2022 | 601 | 0.270 |
Why?
|
| Mice, Transgenic | 4 | 2022 | 1207 | 0.260 |
Why?
|
| Survival Rate | 3 | 2021 | 804 | 0.260 |
Why?
|
| Hydrolases | 2 | 2019 | 81 | 0.250 |
Why?
|
| Base Sequence | 2 | 2022 | 1302 | 0.250 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 349 | 0.250 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2023 | 78 | 0.250 |
Why?
|
| Cell Proliferation | 5 | 2019 | 945 | 0.250 |
Why?
|
| Gene Transfer Techniques | 3 | 2017 | 305 | 0.250 |
Why?
|
| Wnt Signaling Pathway | 2 | 2017 | 72 | 0.250 |
Why?
|
| Mice, Nude | 3 | 2016 | 261 | 0.240 |
Why?
|
| RNA-Directed DNA Polymerase | 2 | 2022 | 34 | 0.240 |
Why?
|
| Mice, Knockout | 5 | 2019 | 2000 | 0.230 |
Why?
|
| Cell Survival | 3 | 2017 | 560 | 0.230 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 217 | 0.230 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 1570 | 0.230 |
Why?
|
| Gene Expression | 4 | 2016 | 811 | 0.230 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 264 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2015 | 321 | 0.230 |
Why?
|
| Nitriles | 2 | 2016 | 62 | 0.220 |
Why?
|
| Genes, Regulator | 1 | 2004 | 28 | 0.220 |
Why?
|
| Mammals | 2 | 2023 | 209 | 0.220 |
Why?
|
| Open Reading Frames | 1 | 2004 | 82 | 0.220 |
Why?
|
| Cell Line | 5 | 2023 | 1987 | 0.220 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2023 | 15 | 0.210 |
Why?
|
| Sequence Alignment | 1 | 2004 | 288 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 9 | 2019 | 3240 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2014 | 180 | 0.200 |
Why?
|
| Nucleotides | 2 | 2020 | 44 | 0.200 |
Why?
|
| Nanoparticles | 4 | 2017 | 492 | 0.200 |
Why?
|
| Ribonuclease H | 1 | 2022 | 18 | 0.190 |
Why?
|
| Biotinylation | 1 | 2022 | 36 | 0.190 |
Why?
|
| Axonal Transport | 1 | 2022 | 31 | 0.190 |
Why?
|
| Biotin | 1 | 2022 | 51 | 0.190 |
Why?
|
| Mucopolysaccharidosis II | 1 | 2021 | 10 | 0.190 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1304 | 0.190 |
Why?
|
| Recombinational DNA Repair | 1 | 2021 | 19 | 0.190 |
Why?
|
| Neisseria meningitidis | 2 | 2018 | 81 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2017 | 194 | 0.180 |
Why?
|
| Ribonucleoproteins | 1 | 2022 | 112 | 0.180 |
Why?
|
| INDEL Mutation | 2 | 2024 | 18 | 0.180 |
Why?
|
| Uridine | 1 | 2020 | 16 | 0.170 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 163 | 0.170 |
Why?
|
| Codon | 1 | 2020 | 48 | 0.170 |
Why?
|
| Codon, Nonsense | 1 | 2020 | 51 | 0.170 |
Why?
|
| Phenotype | 3 | 2020 | 1142 | 0.170 |
Why?
|
| HeLa Cells | 1 | 2021 | 526 | 0.160 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 289 | 0.160 |
Why?
|
| Female | 11 | 2021 | 30925 | 0.160 |
Why?
|
| Integrin beta4 | 1 | 2019 | 31 | 0.160 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 112 | 0.160 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2019 | 26 | 0.160 |
Why?
|
| Mevalonic Acid | 1 | 2018 | 4 | 0.160 |
Why?
|
| Eicosanoids | 1 | 2019 | 25 | 0.160 |
Why?
|
| Metabolomics | 1 | 2019 | 52 | 0.150 |
Why?
|
| Stem Cells | 2 | 2012 | 255 | 0.150 |
Why?
|
| Algorithms | 1 | 2004 | 981 | 0.150 |
Why?
|
| Point Mutation | 1 | 2019 | 161 | 0.150 |
Why?
|
| Genes, Recessive | 1 | 2018 | 49 | 0.150 |
Why?
|
| RNA Polymerase II | 1 | 2018 | 72 | 0.150 |
Why?
|
| Down-Regulation | 1 | 2019 | 308 | 0.150 |
Why?
|
| Phosphoproteins | 3 | 2015 | 213 | 0.150 |
Why?
|
| Mitochondria | 1 | 2021 | 344 | 0.150 |
Why?
|
| Heterozygote | 1 | 2018 | 162 | 0.140 |
Why?
|
| Mitosis | 1 | 2019 | 210 | 0.140 |
Why?
|
| Actins | 1 | 2019 | 259 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 194 | 0.140 |
Why?
|
| Stem Cell Niche | 1 | 2017 | 13 | 0.140 |
Why?
|
| RNA Splicing | 1 | 2018 | 159 | 0.140 |
Why?
|
| CRISPR-Associated Proteins | 2 | 2014 | 31 | 0.140 |
Why?
|
| HMGA2 Protein | 1 | 2016 | 4 | 0.140 |
Why?
|
| HMGA Proteins | 1 | 2016 | 5 | 0.140 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Butadienes | 1 | 2016 | 9 | 0.140 |
Why?
|
| Sequence Deletion | 1 | 2017 | 112 | 0.140 |
Why?
|
| Pyrimidinones | 1 | 2016 | 15 | 0.130 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2022 | 480 | 0.130 |
Why?
|
| Niacinamide | 1 | 2016 | 32 | 0.130 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 30 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 55 | 0.130 |
Why?
|
| Carbon Monoxide | 1 | 2017 | 61 | 0.130 |
Why?
|
| Cisplatin | 2 | 2014 | 120 | 0.130 |
Why?
|
| Respiratory System | 1 | 2017 | 45 | 0.130 |
Why?
|
| Nervous System | 1 | 2017 | 69 | 0.130 |
Why?
|
| Pyridones | 1 | 2016 | 37 | 0.130 |
Why?
|
| Gene Amplification | 1 | 2016 | 23 | 0.130 |
Why?
|
| Cardiovascular System | 1 | 2017 | 38 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2016 | 54 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 193 | 0.130 |
Why?
|
| Nitric Oxide | 1 | 2017 | 146 | 0.130 |
Why?
|
| RNA Editing | 1 | 2016 | 21 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 113 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2017 | 367 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 170 | 0.120 |
Why?
|
| Blotting, Western | 1 | 2016 | 590 | 0.120 |
Why?
|
| RNA | 1 | 2019 | 405 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 195 | 0.120 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 200 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2017 | 146 | 0.120 |
Why?
|
| Chromosome Inversion | 1 | 2015 | 17 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2016 | 558 | 0.120 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2015 | 6 | 0.120 |
Why?
|
| Dendrimers | 1 | 2015 | 11 | 0.120 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 41 | 0.120 |
Why?
|
| Prognosis | 2 | 2016 | 1613 | 0.120 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 180 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2018 | 257 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2015 | 118 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 134 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 335 | 0.120 |
Why?
|
| Nestin | 1 | 2014 | 13 | 0.120 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 857 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 32 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 428 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 418 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 62 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 83 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 360 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 357 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 661 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 191 | 0.100 |
Why?
|
| Nanotechnology | 1 | 2014 | 128 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 203 | 0.100 |
Why?
|
| Nanostructures | 1 | 2015 | 173 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 203 | 0.100 |
Why?
|
| Disease Progression | 1 | 2017 | 1126 | 0.100 |
Why?
|
| Haploinsufficiency | 1 | 2012 | 15 | 0.100 |
Why?
|
| Asthma | 1 | 2017 | 460 | 0.100 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 98 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2014 | 886 | 0.090 |
Why?
|
| Caspase 2 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2008 | 38 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 570 | 0.090 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 37 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 32 | 0.090 |
Why?
|
| Sulfones | 1 | 2011 | 36 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 28 | 0.090 |
Why?
|
| Pyrazines | 1 | 2011 | 33 | 0.090 |
Why?
|
| Bortezomib | 1 | 2011 | 56 | 0.090 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 50 | 0.090 |
Why?
|
| Oligonucleotides | 2 | 2018 | 215 | 0.090 |
Why?
|
| Cysteine Endopeptidases | 1 | 2011 | 92 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1955 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2006 | 297 | 0.090 |
Why?
|
| Apoptosis | 3 | 2019 | 1033 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 2 | 2017 | 196 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2015 | 738 | 0.080 |
Why?
|
| Cadherins | 1 | 2009 | 75 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 1555 | 0.080 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2008 | 4 | 0.080 |
Why?
|
| Genes, myc | 1 | 2008 | 17 | 0.080 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2008 | 7 | 0.070 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2008 | 27 | 0.070 |
Why?
|
| Ubiquitin | 1 | 2008 | 97 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 133 | 0.070 |
Why?
|
| Models, Animal | 1 | 2008 | 224 | 0.070 |
Why?
|
| HCT116 Cells | 2 | 2018 | 48 | 0.070 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 385 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2007 | 383 | 0.060 |
Why?
|
| Multipotent Stem Cells | 1 | 2005 | 13 | 0.060 |
Why?
|
| Immunity, Innate | 2 | 2009 | 774 | 0.060 |
Why?
|
| Founder Effect | 1 | 2024 | 10 | 0.060 |
Why?
|
| Genome, Fungal | 1 | 2004 | 41 | 0.050 |
Why?
|
| Templates, Genetic | 1 | 2023 | 21 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2024 | 68 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 51 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2004 | 171 | 0.050 |
Why?
|
| Substrate Specificity | 2 | 2018 | 333 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2004 | 122 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2004 | 178 | 0.050 |
Why?
|
| Tetanus Toxoid | 1 | 2022 | 14 | 0.050 |
Why?
|
| Deoxyribonuclease I | 1 | 2022 | 40 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 1153 | 0.050 |
Why?
|
| Profilins | 1 | 2022 | 45 | 0.050 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2022 | 133 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2018 | 355 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2022 | 194 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2022 | 213 | 0.040 |
Why?
|
| Male | 5 | 2021 | 27952 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2004 | 482 | 0.040 |
Why?
|
| Integrin alpha6 | 1 | 2019 | 19 | 0.040 |
Why?
|
| Microscopy, Video | 1 | 2019 | 37 | 0.040 |
Why?
|
| Proadifen | 1 | 2019 | 3 | 0.040 |
Why?
|
| Clotrimazole | 1 | 2019 | 9 | 0.040 |
Why?
|
| Azoxymethane | 1 | 2019 | 16 | 0.040 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2004 | 541 | 0.040 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2018 | 6 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2019 | 38 | 0.040 |
Why?
|
| Terpenes | 1 | 2018 | 25 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 57 | 0.040 |
Why?
|
| 4-Hydroxyphenylpyruvate Dioxygenase | 1 | 2018 | 2 | 0.040 |
Why?
|
| Zygote | 1 | 2018 | 44 | 0.040 |
Why?
|
| Embryo Transfer | 1 | 2018 | 23 | 0.040 |
Why?
|
| Transgenes | 1 | 2019 | 177 | 0.040 |
Why?
|
| Nucleotide Motifs | 1 | 2018 | 50 | 0.040 |
Why?
|
| A549 Cells | 1 | 2018 | 36 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2018 | 38 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2018 | 64 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2019 | 123 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 453 | 0.040 |
Why?
|
| Introns | 1 | 2018 | 104 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2018 | 105 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2018 | 89 | 0.040 |
Why?
|
| Protein Binding | 2 | 2015 | 1556 | 0.040 |
Why?
|
| Cell Separation | 1 | 2018 | 145 | 0.040 |
Why?
|
| Cholesterol | 1 | 2018 | 252 | 0.030 |
Why?
|
| DNA Damage | 2 | 2011 | 278 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 160 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 55 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2017 | 234 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1315 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 334 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 645 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 2015 | 2 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2015 | 14 | 0.030 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Species Specificity | 2 | 2006 | 329 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 170 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 259 | 0.030 |
Why?
|
| Viruses | 1 | 2016 | 78 | 0.030 |
Why?
|
| Sp3 Transcription Factor | 1 | 2014 | 2 | 0.030 |
Why?
|
| Sp1 Transcription Factor | 1 | 2014 | 21 | 0.030 |
Why?
|
| Lentivirus | 1 | 2014 | 63 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2015 | 174 | 0.030 |
Why?
|
| Lipids | 1 | 2016 | 301 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2014 | 255 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 187 | 0.030 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2011 | 4 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 59 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 312 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 225 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2009 | 16 | 0.020 |
Why?
|
| Karyopherins | 1 | 2008 | 7 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2008 | 17 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2008 | 33 | 0.020 |
Why?
|
| Peptide Initiation Factors | 1 | 2008 | 31 | 0.020 |
Why?
|
| Hepatic Stellate Cells | 1 | 2009 | 23 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2008 | 9 | 0.020 |
Why?
|
| Luciferases | 1 | 2008 | 107 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 170 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2008 | 97 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2008 | 101 | 0.020 |
Why?
|
| Carcinoma | 1 | 2008 | 117 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 179 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 164 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 490 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 656 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 697 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 608 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2006 | 105 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 99 | 0.020 |
Why?
|
| Kidney | 1 | 2008 | 424 | 0.020 |
Why?
|
| Cell Division | 1 | 2007 | 444 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 588 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 186 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 387 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2005 | 78 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 870 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2006 | 302 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 476 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 5334 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2005 | 228 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 691 | 0.010 |
Why?
|
| Aged | 1 | 2009 | 13510 | 0.010 |
Why?
|
| Adult | 1 | 2009 | 15771 | 0.010 |
Why?
|
| Middle Aged | 1 | 2009 | 16449 | 0.010 |
Why?
|